RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial

Enisamium is an orally available therapeutic that inhibits influenza A virus and SARS-CoV-2 replication. We evaluated the clinical efficacy of enisamium treatment combined with standard care in adult, hospitalized patients with moderate COVID-19 requiring external oxygen. Hospitalized patients with...

Full description

Bibliographic Details

Published in:	Advances in Respiratory Medicine
Main Authors:	Olga Holubovska, Pavlo Babich, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Lutz Mueller, Aartjan J. W. te Velthuis, Victor Margitich, Andrew Goy
Format:	Article
Language:	English
Published:	MDPI AG 2024-05-01
Subjects:	COVID-19 SARS-CoV-2 clinical trial RNA polymerase antiviral FAV00A
Online Access:	https://www.mdpi.com/2543-6031/92/3/21